Pharmacist-Involved Collaborative Care Benefits T2DM

This article originally appeared here.
Share this content:
Pharmacist-Involved Collaborative Care Benefits T2DM
Pharmacist-Involved Collaborative Care Benefits T2DM

MONDAY, May 15, 2017 (HealthDay News) -- Multidisciplinary collaborative care with pharmacist follow-up is beneficial for Asian patients with uncontrolled type 2 diabetes, according to a study published online April 27 in the Journal of Clinical Pharmacy and Therapeutics.

Melanie Y.L. Siaw, from the National University of Singapore, and colleagues conducted a six-month prospective randomized trial at four outpatient health care institutions involving high-risk patients aged 21 years and older with uncontrolled type 2 diabetes, polypharmacy, and comorbidities. Four hundred eleven patients were randomized to receive either usual care with referrals to nurses and dieticians as needed (control arm, 197 patients) or multidisciplinary collaborative care with regular follow-up from pharmacists as well as usual care (intervention, 214 patients).

The researchers observed a mean reduction of hemoglobin A1c (HbA1c) in the intervention arm, from 8.6 ± 1.5 percent at baseline to 8.1 ± 1.3 percent at six months (P = 0.04); in patients with greater levels of uncontrolled glycemia, the mean HbA1c improvement was up to 0.8 percent. In the control arm, the mean HbA1c remained unchanged throughout the follow-up period (8.5 ± 1.4 percent). Over six months, the intervention arm also had improvements in Problem Areas in Diabetes and the Diabetes Treatment Satisfaction Questionnaires, reduction in physician workload, and an average reduction in cost of $91.01 per patient.

"The positive clinical, humanistic, and economic outcomes highlighted the value of multidisciplinary collaborative care for Asian diabetic patients," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths